What the FDA labels say about taking them together
Edoxaban and rifampin
Edoxaban's FDA label of July 10, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name edoxaban. The edoxaban label: “Avoid concomitant use due to increased risk of bleeding. Rifampin: Avoid concomitant use”
Check it at the source: the edoxaban FDA label on DailyMed (effective July 10, 2025, Daiichi Sankyo Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the edoxaban label say about rifampin?
Edoxaban label, drug interactionsAvoid concomitant use due to increased risk of bleeding. ( 7.1 ) Rifampin: Avoid concomitant use
Source: FDA drug label (SAVAYSA), Daiichi Sankyo Inc., effective July 10, 2025 (SPL set e77d3400-56ad-11e3-949a-0800200c9a66), via openFDA; the full label on DailyMed
What does the rifampin label say about edoxaban?
Rifampin's label (effective February 11, 2026) does not name edoxaban in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Edoxaban | Rifampin | |
|---|---|---|
| Labeled for | Atrial fibrillation, Stroke prevention, Blood clots (DVT and PE) | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $15.51 per tablet 60 mg tablet | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once